Your browser doesn't support javascript.
loading
Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases.
Ugai, Tomotaka; Akimoto, Naohiko; Haruki, Koichiro; Harrison, Tabitha A; Cao, Yin; Qu, Conghui; Chan, Andrew T; Campbell, Peter T; Berndt, Sonja I; Buchanan, Daniel D; Cross, Amanda J; Diergaarde, Brenda; Gallinger, Steven J; Gunter, Marc J; Harlid, Sophia; Hidaka, Akihisa; Hoffmeister, Michael; Brenner, Hermann; Chang-Claude, Jenny; Hsu, Li; Jenkins, Mark A; Lin, Yi; Milne, Roger L; Moreno, Victor; Newcomb, Polly A; Nishihara, Reiko; Obon-Santacana, Mireia; Pai, Rish K; Sakoda, Lori C; Schoen, Robert E; Slattery, Martha L; Sun, Wei; Amitay, Efrat L; Alwers, Elizabeth; Thibodeau, Stephen N; Toland, Amanda E; Van Guelpen, Bethany; Zaidi, Syed H; Potter, John D; Meyerhardt, Jeffrey A; Giannakis, Marios; Song, Mingyang; Nowak, Jonathan A; Peters, Ulrike; Phipps, Amanda I; Ogino, Shuji.
Affiliation
  • Ugai T; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA. tugai@bwh.harvard.edu.
  • Akimoto N; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. tugai@bwh.harvard.edu.
  • Haruki K; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
  • Harrison TA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
  • Cao Y; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Qu C; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
  • Chan AT; Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Campbell PT; Alvin J. Siteman Cancer Center, St Louis, MO, USA.
  • Berndt SI; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Buchanan DD; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Cross AJ; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
  • Diergaarde B; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Gallinger SJ; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Gunter MJ; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Harlid S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Hidaka A; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia.
  • Hoffmeister M; Victorian Comprehensive Cancer Centre, University of Melbourne Centre for Cancer Research, Parkville, VIC, Australia.
  • Brenner H; Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, VIC, Australia.
  • Chang-Claude J; Department of Epidemiology and Biostatistics, Imperial College London, Norfolk Place, London, UK.
  • Hsu L; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Jenkins MA; Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
  • Lin Y; Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France.
  • Milne RL; Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.
  • Moreno V; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Newcomb PA; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Nishihara R; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Obon-Santacana M; Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Pai RK; German Cancer Consortium (Deutschen Konsortium für Translationale Krebsforschung), German Cancer Research Center (Deutsches Krebsforschungszentrum), Heidelberg, Germany.
  • Sakoda LC; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schoen RE; Cancer Epidemiology Group, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Slattery ML; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Sun W; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Amitay EL; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Alwers E; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Thibodeau SN; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Toland AE; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
  • Van Guelpen B; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Zaidi SH; Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Potter JD; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029, Madrid, Spain.
  • Meyerhardt JA; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
  • Giannakis M; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Song M; Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Nowak JA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 404, Boston, MA, 02215, USA.
  • Peters U; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Phipps AI; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Ogino S; Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
J Gastroenterol ; 58(3): 229-245, 2023 03.
Article in En | MEDLINE | ID: mdl-36648535
ABSTRACT

BACKGROUND:

The pathogenic effect of colorectal tumor molecular features may be influenced by several factors, including those related to microbiota, inflammation, metabolism, and epigenetics, which may change along colorectal segments. We hypothesized that the prognostic association of colon cancer location might differ by tumor molecular characteristics.

METHODS:

Utilizing a consortium dataset of 13,101 colorectal cancer cases, including 2994 early-onset cases, we conducted survival analyses of detailed tumor location stratified by statuses of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF oncogenic mutation.

RESULTS:

There was a statistically significant trend for better colon cancer-specific survival in relation to tumor location from the cecum to sigmoid colon (Ptrend = 0.002), excluding the rectum. The prognostic association of colon location differed by MSI status (Pinteraction = 0.001). Non-MSI-high tumors exhibited the cecum-to-sigmoid trend for better colon cancer-specific survival [Ptrend < 0.001; multivariable hazard ratio (HR) for the sigmoid colon (vs. cecum), 0.80; 95% confidence interval (CI) 0.70-0.92], whereas MSI-high tumors demonstrated a suggestive cecum-to-sigmoid trend for worse survival (Ptrend = 0.020; the corresponding HR, 2.13; 95% CI 1.15-3.92). The prognostic association of colon tumor location also differed by CIMP status (Pinteraction = 0.003) but not significantly by age, stage, or other features. Furthermore, MSI-high status was a favorable prognostic indicator in all stages.

CONCLUSIONS:

Both detailed colonic location and tumor molecular features need to be accounted for colon cancer prognostication to advance precision medicine. Our study indicates the important role of large-scale studies to robustly examine detailed colonic subsites in molecular oncology research.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2023 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2023 Document type: Article Affiliation country: Estados Unidos